• Demethyleneberberine as a Multi-Pathway Candidate for Huntin

  2026-05-28

  This article examines the proposed use of Demethyleneberberine (DMB), a natural isoquinoline alkaloid, as a multi-target therapeutic agent for Huntington’s disease (HD). The reference study offers mechanistic insights into DMB’s ability to modulate oxidative stress, neuroinflammation, and mitochondrial dysfunction, highlighting its translational potential for neurodegenerative research.

• Ertugliflozin (PF-04971729): Advanced Diabetes Research Work

  2026-05-28

  Ertugliflozin (PF-04971729) empowers researchers with unmatched SGLT2 selectivity and protocol flexibility for diabetes and cardiometabolic studies. This guide translates recent cardiovascular and mechanistic findings into actionable workflows, troubleshooting strategies, and cross-domain research insights.

• Phosbind Acrylamide: Accelerating Protein Phosphorylation An

  2026-05-27

  Phosbind Acrylamide enables precise, antibody-free detection of protein phosphorylation states via SDS-PAGE, streamlining workflows for signal transduction and kinase activity studies. Its unique phosphate-binding mechanism empowers researchers to resolve phosphorylated isoforms efficiently, as demonstrated in advanced plant signaling research and translational studies.

• Dutasteride as a Dual 5-Alpha-Reductase Inhibitor in Prostat

  2026-05-27

  Dutasteride, a potent dual 5-alpha-reductase inhibitor, is pivotal for dissecting androgen-driven mechanisms in prostate cancer and BPH research. This article delivers stepwise experimental protocols, troubleshooting tactics, and cross-study insights to maximize assay reliability, with reference to recent advances in apoptotic pathway modulation and immunometabolic concepts.

• Canagliflozin Hemihydrate: Defining Specificity in Glucose R

  2026-05-26

  Explore the scientific rigor and unique specificity of Canagliflozin hemihydrate in glucose metabolism research. This article delivers in-depth analysis, advanced assay decision-making, and direct insights from cutting-edge mTOR pathway studies.

• A20 Restricts Oxidized Self-DNA Inflammation in Acute Kidney

  2026-05-26

  This study identifies the ubiquitin-editing enzyme A20 as a critical suppressor of oxidized self-DNA-induced inflammation during acute kidney injury (AKI). By uncovering a mechanism in which A20 disrupts NEK7/NLRP3 inflammasome assembly, the results highlight a therapeutic strategy for mitigating AKI progression and sterile inflammation.

• SB 431542: ALK5 Inhibitor Workflows for TGF-β Pathway Resear

  2026-05-25

  SB 431542 stands out as a selective ALK5 inhibitor, empowering researchers to dissect TGF-β signaling in both cancer immunology and regenerative biology. This article translates advanced findings—like those from cryoablation-mediated immune modulation—into actionable protocols and troubleshooting strategies, maximizing the compound’s reliability for bench-to-impact studies.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-05-25

  This study provides a detailed molecular and epidemiological analysis of carbapenemase-encoding gene (CEG) distribution and transmission in carbapenem-resistant Enterobacter cloacae (CREC) across eight hospitals in Guangdong, China. The findings reveal the dominance of blaNDM−1 genes, high rates of plasmid-mediated resistance transfer, and multidrug resistance phenotypes, offering critical insights for antimicrobial resistance research and infection control.

• Canagliflozin in Renal Bioenergetics: Beyond Glucose Lowerin

  2026-05-24

  Explore how Canagliflozin, a potent SGLT2 inhibitor, advances diabetes and kidney research by modulating mitochondrial function in proximal tubular cells. This article uniquely details bioenergetic remodeling, practical assay insights, and protocol guidance for investigators.

• Fucoidan in Translational Oncology: Mechanistic Depth and St

  2026-05-23

  This thought-leadership article explores the complex bioactivity of Fucoidan (APExBIO, SKU C4038) as a sulfated α-L-fucan from brown seaweed, emphasizing its multi-pathway anticancer and immune-modulating mechanisms. Drawing on recent mechanistic studies and workflow-driven resources, the article provides actionable guidance for translational researchers seeking to bridge discovery with clinical impact. It highlights protocol parameters for optimal use, assesses the competitive landscape, and articulates a future-facing vision while grounding all claims in credible, cited evidence.

• Omeprazole (A2845): Technical Guide for Gastric Acid Researc

  2026-05-22

  Omeprazole, identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU A2845), is a potent H+,K+-ATPase inhibitor purpose-built for research on gastric acid secretion and antiulcer activity. It should not be used for diagnostic or therapeutic applications, nor substituted for clinical-grade formulations. Its primary utility lies in preclinical, mechanistic, and translational workflows related to gastric acid-related disorders.

• Omeprazole (A2845): Technical Guide for Gastric Acid Researc

  2026-05-22

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor designed for controlled research on gastric acid secretion, antiulcer mechanisms, and peptic ulcer disease models. It should not be used for diagnostic or medical applications; instead, it is best suited to in vitro and in vivo mechanistic studies with rigorous protocol adherence.

• Ferrostatin-1 (Fer-1): Epigenetic Advances in Ferroptosis In

  2026-05-21

  Explore how Ferrostatin-1 (Fer-1) advances ferroptosis assay design by modulating DNA methylation and TET activity. This article reveals unique epigenetic and mechanistic insights for oxidative lipid damage inhibition in disease models.

• Dextrose (D-glucose) in Tumor Immunometabolism & Assay Desig

  2026-05-21

  Dextrose (D-glucose) is the cornerstone for modeling energy metabolism and dissecting hypoxia-driven immunometabolic reprogramming in advanced cellular assays. With exceptional purity and reproducibility, it empowers both foundational and cutting-edge workflows, from cell culture supplementation to tumor microenvironment studies.

• Applied Insights: Ertugliflozin (PF-04971729) in Diabetes Re

  2026-05-20

  Ertugliflozin (PF-04971729) stands out for its exceptional selectivity and translational flexibility in both diabetes and renal glucose transport studies. This article delivers protocol-ready recommendations, comparative workflow analysis, and troubleshooting strategies for maximizing experimental reliability with this SGLT2 inhibitor.

15985 records 1/1066 page Next 12345 下5页 Last page